Anton Neschadim

Anton Neschadim is the current CEO of Nanovista, and they have also held positions at GreenSky Capital Inc. and Armour Therapeutics Inc.

Neschadim began their career in 2010 as the Director of Drug Development for Armour Therapeutics Inc., a biopharmaceutical company focused on developing new anti-hormone therapeutics to treat reproductive tissue-based cancers. During their five years with the company, Neschadim played a key role in developing Armour's lead compound, AT-001, as well as compounds for the AT-012 and AT-027 programs targeting breast and ovarian cancers, respectively.

In 2015, Neschadim left Armour Therapeutics to join GreenSky Capital Inc. as a managing partner. Anton remained with GreenSky for two years before moving on to become the CEO of Nanovista in 2017.

Under Neschadim's leadership, Nanovista has quickly become a leading player in the nanotechnology space, with a focus on developing innovative solutions for the healthcare industry. In just a few short years, Nanovista has made significant progress in developing new nanomedicines and delivery systems that have the potential to revolutionize the way we treat diseases.

Anton Neschadim has completed a certificate in Mergers & Acquisitions from Harvard Business School Executive Education, an executive program in Leadership from Stanford University Graduate School of Business, an executive education in Negotiation Strategies from Yale School of Management, and a certificate in Value Measurement for Health Care from Harvard Business School Executive Education. Anton also holds a Master of Business Administration (M.B.A.) from University of Toronto - Rotman School of Management, a PhD from University of Toronto, and an MSc from University of Toronto. Finally, they hold an Hon. B.Sc. from University of Toronto - University College.

Some direct reports include Christine Allen - Director & Co-Founder, David Jaffray - Director & Co-Founder, and Jinzi Zheng - Director & Co-Founder.